J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
Executive Summary
Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.
You may also be interested in...
Pipeline Watch: Phase III Progress With Biosimilar Adalimumab And Trastuzumab
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.
Timeline: Expected Clinical Trial Readouts For PD-1 Competitors
Scrip highlights the top data readouts expected over the next 12 months from the big PD-1/PD-L1 players, such as Bristol Myers Squibb and Merck & Co. – as well as a few compounds to watch out for earlier in the cancer immunotherapy pipeline.